NIVOPOST-OP: First Breakthrough in High-Risk Resected HNSCC in 20 Years

For over 20 years, the standard of care for high-risk resected head and neck cancer has been postoperative chemoradiation. Despite aggressive treatment, 40-45% of patients relapse within 2 years.

NIVOPOST-OP finally changes that.

This phase 3 trial (n=666) randomized high-risk resected LA-SCCHN patients to standard chemoRT vs. chemoRT + nivolumab (concurrent + adjuvant).

The Results: - 3-year DFS: 63.1% vs 52.5% - HR 0.76 (p=0.034) - Benefit driven by reduced locoregional relapses (HR 0.63)

Key Insight: Unlike the metastatic setting, PD-L1 status did NOT predict benefit. All subgroups benefited equally.

Safety: Modest increase in Grade 3-4 AEs, but NO increase in treatment-related deaths.

Bottom Line: Adjuvant nivolumab can be proposed as a new standard of care for high-risk resected HNSCC. This addresses a 20-year therapeutic gap.

🎧 Listen to the 5-minute breakdown: https://hnoncology-journalclub.netlify.app/episode-004.html

— Dr. Krishnakumar Thankappan Head & Neck Oncology Journal Club